Novavax Smashes Q1 2026 Revenue Expectations with Big Vaccine Tech Deals
Novavax beat forecasts with $140M revenue, boosted by vaccine tech deals, new partnerships, and strong cash position.
/ 18 items
#XY Earnings Movers↓
CVS Health Raises 2026 Guidance After Strong Q1 Beat and Better Cost Controls
CVS had strong Q1: revenue $100.4B, earnings beat expectations, raised outlook, cash flow up. Stock rose.
Novo Nordisk Raises Full-Year Guidance After Strong Wegovy Pill Launch
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
Tempus AI Q1 2026: Revenue Beats Expectations, But Stock Drops on Wider Losses
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
Summit Therapeutics Drops 21%: The “Continue” News That Spooked Investors
Summit stock fell after its cancer drug update was just “keep going,” not the big win investors hoped for.
Moderna Beats Q1 2026 Revenue Estimates as International Sales Surge, Stock Jumps
Moderna beat Q1 revenue on strong overseas COVID vaccine sales, revenue $389M, smaller US demand, reported a per-share loss.